Edgewise Therapeutics

Webinar Recording: Edgewise Therapeutics – Update on Sevasemten Program in Becker and Duchenne

Edgewise Therapeutics recently joined PPMD for a community webinar for an update on the company’s sevasemten program in Duchenne and Becker. The Edgewise team reviewed new Open-label Extension MESA data in Becker, as well as…

Learn More

Edgewise Therapeutics Shares Positive Results on Sevasemten Program for Becker and Duchenne

Edgewise Therapeutics, Inc., has announced positive results in the company’s sevasemten program for both Becker and Duchenne. These data include results from: MESA, an open label extension trial of participants with Becker who were previously…

Learn More

December 19, 2024

WATCH: Sevasemten – CANYON Trial Topline Results (Webinar Recording)

Edgewise Therapeutics recently joined PPMD for a breaking news community webinar, during which Edgewise provided an update on the recently released topline results from its CANYON double-blind, randomized, placebo-controlled design to investigate the effect of…

Learn More

December 16, 2024

Edgewise Therapeutics Announces Positive Topline Results from CANYON Phase 2 Trial of Sevasemten in Individuals with Becker

Edgewise Therapeutics, Inc., has announced positive topline results from the double-blind, randomized, placebo-controlled Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered small molecule inhibitor designed to…

Learn More

WATCH: Edgewise Therapeutics – Clinical Trials in Becker Muscular Dystrophy (Webinar)

Edgewise Therapeutics recently joined PPMD for a webinar to provide the Becker community information about the company’s clinical trials for Becker. Edgewise’s Chief Scientific Officer and Chief Medical Officer, shared two year results from the…

Learn More

Edgewise Therapeutics Announces Positive Two-Year Topline Results from ARCH Study of EDG-5506

Edgewise Therapeutics, Inc., has announced positive two-year topline results from the ARCH open label study of sevasemten (EDG-5506) in adults with Becker. Sevasemten is an orally administered small molecule inhibitor designed to prevent contraction-induced muscle…

Learn More

October 27, 2023

Edgewise Therapeutics Announces Expansion of their EDG-5506 Clinical Program in Duchenne

Edgewise Therapeutics, Inc. has announced an expansion of their clinical development program of EDG-5506. EDG-5506, which comes in the form of a small pill, is an investigational product that aims to protect muscles, specifically fast-twitch…

Learn More

October 24, 2023

WATCH: Edgewise Therapeutics: A Novel Approach Designed to Protect Muscle in Becker (Webinar Recording)

Edgewise Therapeutics joined PPMD for a community webinar on October 18, 2023 to discuss the company’s investigational compound, EDG-5506. Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer at Edgewise, and Alan Russell, Ph.D., Edgewise’s Co-Founder and…

Learn More

September 26, 2023

Edgewise Therapeutics Now Enrolling GRAND CANYON Study of EDG-5506 in Individuals with Becker Muscular Dystrophy

Edgewise Therapeutics has announced the start of enrollment of GRAND CANYON, the company’s global pivotal study of EDG-5506 in individuals with Becker. GRAND CANYON is an expansion of the CANYON study, which was over-enrolled. EDG-5506…

Learn More

Edgewise Therapeutics announces positive topline 12-month data from EDG-5506 ARCH study

Edgewise Therapeutics today announced topline 12-month data from the ARCH study of EDG-5506, an orally administered small molecule designed to prevent contraction-induced muscle damage in patients with Becker muscular dystrophy. The ARCH study is evaluating…

Learn More

Join Our Mailing List